TherapeuticsMD Analyst Ratings
TherapeuticsMD Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/17/2023 | 39.66% | Cantor Fitzgerald | → $5 | Reiterates | Neutral → Neutral |
| 01/11/2023 | 39.66% | Cantor Fitzgerald | → $5 | Reinstates | → Neutral |
| 07/13/2022 | -72.07% | Cantor Fitzgerald | → $1 | Reiterates | → Neutral |
| 06/07/2022 | 179.33% | HC Wainwright & Co. | → $10 | Downgrades | Buy → Neutral |
| 05/06/2022 | -72.07% | Cantor Fitzgerald | $5 → $1 | Downgrades | Overweight → Neutral |
| 03/11/2022 | -30.17% | HC Wainwright & Co. | $3 → $2.5 | Maintains | Buy |
| 11/12/2021 | -16.2% | HC Wainwright & Co. | $4 → $3 | Maintains | Buy |
| 08/07/2020 | -66.48% | Jefferies | $1.25 → $1.2 | Downgrades | Hold → Underperform |
| 05/19/2020 | — | JP Morgan | Downgrades | Overweight → Neutral | |
| 05/07/2020 | 39.66% | HC Wainwright & Co. | $6 → $5 | Reiterates | → Buy |
| 04/16/2020 | 318.99% | Stifel | $14 → $15 | Maintains | Buy |
| 02/21/2020 | 67.6% | HC Wainwright & Co. | $7 → $6 | Maintains | Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 08/17/2023 | 39.66% | 坎託·菲茨傑拉德 | → 5 美元 | 重申 | 中性 → 中性 |
| 2023 年 11 月 1 日 | 39.66% | 坎託·菲茨傑拉德 | → 5 美元 | 恢復 | → 中立 |
| 07/13/2022 | -72.07% | 坎託·菲茨傑拉德 | → 1 美元 | 重申 | → 中立 |
| 2022 年 7 月 6 日 | 179.33% | HC Wainwright & Co. | → 10 美元 | 降級 | 買入 → 中性 |
| 2022 年 6 月 5 日 | -72.07% | 坎託·菲茨傑拉德 | 5 美元 → 1 美元 | 降級 | 超重 → 中性 |
| 03/11/2022 | -30.17% | HC Wainwright & Co. | $3 → 2.5 美元 | 維護 | 購買 |
| 11/12/2021 | -16.2% | HC Wainwright & Co. | 4 美元 → 3 美元 | 維護 | 購買 |
| 08/07/2020 | -66.48% | 傑富瑞 | 1.25 美元 → 1.2 美元 | 降級 | 持有 → 表現不佳 |
| 2020 年 5 月 19 日 | — | 摩根大通 | 降級 | 超重 → 中性 | |
| 05/07/2020 | 39.66% | HC Wainwright & Co. | 6 美元 → 5 美元 | 重申 | → 購買 |
| 2020 年 4 月 16 日 | 318.99% | Stifel | 14 美元 → 15 美元 | 維護 | 購買 |
| 02/21/2020 | 67.6% | HC Wainwright & Co. | 7 美元 → 6 美元 | 維護 | 購買 |
What is the target price for TherapeuticsMD (TXMD)?
TherapeicsMD（TXMD）的目標價格是多少？
The latest price target for TherapeuticsMD (NASDAQ: TXMD) was reported by Cantor Fitzgerald on August 17, 2023. The analyst firm set a price target for $5.00 expecting TXMD to rise to within 12 months (a possible 39.66% upside). 2 analyst firms have reported ratings in the last year.
坎託·菲茨傑拉德於2023年8月17日公佈了TherapeicsMD（納斯達克股票代碼：TXMD）的最新目標股價。該分析公司將目標股價定爲5.00美元，預計TXMD將在12個月內上漲至39.66％（可能上漲39.66％）。去年，有2家分析公司公佈了評級。
What is the most recent analyst rating for TherapeuticsMD (TXMD)?
TherapeicsMD（TXMD）的最新分析師評級是多少？
The latest analyst rating for TherapeuticsMD (NASDAQ: TXMD) was provided by Cantor Fitzgerald, and TherapeuticsMD reiterated their neutral rating.
坎託·菲茨傑拉德提供了TherapeicsMD（納斯達克股票代碼：TXMD）的最新分析師評級，TherapeicsMD重申了中性評級。
When is the next analyst rating going to be posted or updated for TherapeuticsMD (TXMD)?
TherapeicsMD（TXMD）的下一份分析師評級何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of TherapeuticsMD, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for TherapeuticsMD was filed on August 17, 2023 so you should expect the next rating to be made available sometime around August 17, 2024.
分析師在進行了廣泛的研究後得出了股票評級，包括閱讀公開財務報表、與TherapeicsMD的高管和客戶交談以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。TherapeicsMD的最後一次評級是在2023年8月17日提交的，因此你應該預計下一個評級將在2024年8月17日左右公佈。
Is the Analyst Rating TherapeuticsMD (TXMD) correct?
分析師評級 TherapeicsMD (TXMD) 是否正確？
While ratings are subjective and will change, the latest TherapeuticsMD (TXMD) rating was a reiterated with a price target of $0.00 to $5.00. The current price TherapeuticsMD (TXMD) is trading at is $3.58, which is within the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但重申了最新的TherapeicsMD（TXMD）評級，目標股價爲0.00美元至5.00美元。TherapeicsMD（TXMD）目前的交易價格爲3.58美元，在分析師的預測區間內。
譯文內容由第三人軟體翻譯。